ALS CURE PROJECT INC

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2019

Legal Domicile

Principal Officer

Mike Piscotty

Phone

9253215487

Tax Period

2023-01-01 to 2023-12-31

ALS CURE PROJECT INC, founded in 2019, is a small nonprofit in the Medical Research sector that reported $164K in total revenue in fiscal year 2023. Expenses of $244K exceeded revenue, resulting in a 49% operating deficit.

Mission

This year the ALS Cure Project has funded multi-gene modeling at Stanford University and Sheffield University as funding research utilizing Sierram, the Lawerence Livermore Natonal Lab supercomputer, in multi-modal longitudinal modeling and physics-based modeling of TDP-43 protein and Organoid and Assembloid research.

Program Service Accomplishments

Program 1

Expenses: $20,000

ALS Cure Project continued to fund the Physics based modeling project using the worlds fastest supercomputer at Lawerance Livermore Lab to help idenity and understand the ALS disease mechanism. The initial focus will be on the formation of the aberrant TAR DNA- binding protien 43 TDP-43 inclusions or cluster that transition into pathological, amyyloid-like fibrils

Program 2

Expenses: $100,000

ALS Cure Project funded seed research in Organoids and Assembloids from the 2023 Innovation Symposium that we host. The research will use cortico-motor assembloids to investigate the contribution of cortical neuronal hyperactivity to ALS phentypes, to ultimately pinpoint molecular pathways contributing to motor neuron degeneration

Program 3

Expenses: $73,000

The ALS Cure Project seeded 2 research project Barrow Neuro and Triparite selected from the ALS Innovation Symposim held virtual on November 17th and December 1stof 2021 that included 115...

The ALS Cure Project seeded 2 research project Barrow Neuro and Triparite selected from the ALS Innovation Symposim held virtual on November 17th and December 1stof 2021 that included 115 international ALS researchers from 10 nations where participants worked collaboratively in workshop styled breakouts to create the symposiums product. The event was also co-sponsored by Mitsubishi Tanabe Pharma America MTPA

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $51,469

Program Service Revenue $0

Investment Income $0

Other Revenue $113,020

TOTAL REVENUE $164,489

Expense Breakdown

Grants Paid $238,000

Salaries & Benefits $0

Fundraising Expenses $4,783

Program Expenses $238,000

Other Expenses $6,328

TOTAL EXPENSES $244,328

Year-over-Year Comparison

	2023	2022	Change
Revenue	$164,489	$158,344	+0.0%
Expenses	$244,328	$245,563	0.0%
Net Income	$-79,839	$-87,219	-0.1%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Mike Piscotty	President	010.00	Officer Director	$0	$0	$0
Stephen Piscotty	VIce President	001.00	Director	$0	$0	$0
Toni Eslick	Secretary	006.00	Director	$0	$0	$0
James Gilbreth	Fund Raising Director	006.00	Director	$0	$0	$0
Barron Wesenberg	Treasurer	003.00	Director	$0	$0	$0
Andrew Woodward	IT Communications Director	003.00	Director	$0	$0	$0
Dave Darby	Corporate Sponsorship Director	003.00	Director	$0	$0	$0
Jim Poole	Strategic Partnership Director	003.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	No data	No data	No data	No data
2023	$164,489	$244,328	$98,318	$-79,839
2022	$158,344	$245,563	$178,157	$-87,219
2021	$404,785	$232,019	$265,376	$172,766
2020	$523,773	$431,163	$92,610	$92,610